These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 15452269)

  • 21. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
    Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
    Asbach B; Kibler KV; Köstler J; Perdiguero B; Yates NL; Stanfield-Oakley S; Tomaras GD; Kao SF; Foulds KE; Roederer M; Seaman MS; Montefiori DC; Parks R; Ferrari G; Forthal DN; Phogat S; Tartaglia J; Barnett SW; Self SG; Gottardo R; Cristillo AD; Weiss DE; Galmin L; Ding S; Heeney JL; Esteban M; Jacobs BL; Pantaleo G; Wagner R
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses.
    Huang X; Liu L; Ren L; Qiu C; Wan Y; Xu J
    Vaccine; 2007 Dec; 25(52):8874-84. PubMed ID: 18061316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
    Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M
    Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genital CD8+ T cell response to HIV-1 gag in mice immunized by mucosal routes with a recombinant simian adenovirus.
    de Souza AP; Haut LH; Silva R; Ferreira SI; Zanetti CR; Ertl HC; Pinto AR
    Vaccine; 2007 Jan; 25(1):109-16. PubMed ID: 16914235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
    Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
    Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes.
    Xu J; Ren L; Huang X; Qiu C; Liu Y; Liu Y; Shao Y
    AIDS; 2006 Nov; 20(18):2293-303. PubMed ID: 17117015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.
    Koup RA; Roederer M; Lamoreaux L; Fischer J; Novik L; Nason MC; Larkin BD; Enama ME; Ledgerwood JE; Bailer RT; Mascola JR; Nabel GJ; Graham BS; ;
    PLoS One; 2010 Feb; 5(2):e9015. PubMed ID: 20126394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.
    Akahata W; Yang ZY; Nabel GJ
    J Virol; 2005 Jan; 79(1):626-31. PubMed ID: 15596858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunogenicity of a chimeric adenovirus type 5 vector with type 35 fiber containing HIV-1 gag in mice].
    Liu XL; Yu SQ; Feng X; Wang XL; Liu HM; Zhang XM; Li HX; Zhou L; Li ZL; Zheng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):5-7. PubMed ID: 17429520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.
    Walsh SR; Moodie Z; Fiore-Gartland AJ; Morgan C; Wilck MB; Hammer SM; Buchbinder SP; Kalams SA; Goepfert PA; Mulligan MJ; Keefer MC; Baden LR; Swann EM; Grant S; Ahmed H; Li F; Hertz T; Self SG; Friedrich D; Frahm N; Liao HX; Montefiori DC; Tomaras GD; McElrath MJ; Hural J; Graham BS; Jin X;
    J Infect Dis; 2016 Feb; 213(4):541-50. PubMed ID: 26475930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic mobilization of antigen presenting cells, with a chimeric Flt-3 and G-CSF receptor agonist, during immunization of Macaca mulatta with HIV-1 antigens is insufficient to modulate immune responses or vaccine efficacy.
    Koopman G; Mortier D; Niphuis H; Farese AM; Kahn LE; Mann D; Wagner R; MacVittie TJ; Woulfe SL; Heeney JL
    Vaccine; 2005 Jul; 23(33):4195-202. PubMed ID: 15896883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
    Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short communication: enhancement of immunogenicity of replication-defective adenovirus-based human immunodeficiency virus vaccines in rhesus monkeys.
    Sun C; Zhang Y; Liu Y; Zhang M; Chen L
    AIDS Res Hum Retroviruses; 2011 Jun; 27(6):681-6. PubMed ID: 21083437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine.
    Quirk EK; Mogg R; Brown DD; Lally MA; Mehrotra DV; DiNubile MJ; Robertson MN
    Clin Infect Dis; 2008 Dec; 47(12):1593-9. PubMed ID: 18990058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.
    Paris RM; Kim JH; Robb ML; Michael NL
    Expert Rev Vaccines; 2010 Sep; 9(9):1055-69. PubMed ID: 20822348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting.
    Rollier C; Verschoor EJ; Paranhos-Baccala G; Drexhage JA; Verstrepen BE; Berland JL; Himoudi N; Barnfield C; Liljestrom P; Lasarte JJ; Ruiz J; Inchauspe G; Heeney JL
    J Infect Dis; 2005 Sep; 192(5):920-9. PubMed ID: 16088843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys.
    Liu J; Ewald BA; Lynch DM; Denholtz M; Abbink P; Lemckert AA; Carville A; Mansfield KG; Havenga MJ; Goudsmit J; Barouch DH
    J Virol; 2008 May; 82(10):4844-52. PubMed ID: 18337575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice.
    Zhao HP; Sun JF; Li N; Sun Y; Wang Y; Qiu HJ
    Vet Immunol Immunopathol; 2009 Oct; 131(3-4):158-66. PubMed ID: 19411115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.
    Wang X; Uto T; Akagi T; Akashi M; Baba M
    J Virol; 2007 Sep; 81(18):10009-16. PubMed ID: 17609261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.